News Johnson & Johnson Bolsa De Valores De Colombia

Equities

JNJ

US4781601046

End-of-day quote Bolsa De Valores De Colombia Other stock markets 23:00:00 19/06/2024 BST			5-day change	1st Jan Change
604,220 ^COP	0.00%		+0.32%	-0.74%

07:49pm	Sector Update: Health Care Stocks Edge Up in Afternoon Trading	MT
02:39pm	Johnson & Johnson: filing in Crohn's disease	CF

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sector Update: Health Care Stocks Edge Up in Afternoon Trading	06:49pm	MT
Johnson & Johnson: filing in Crohn's disease	01:39pm	CF
Johnson & Johnson: acquisition of Proteologix completed	01:19pm	CF
Johnson & Johnson Completes Acquisition of Proteologix	01:17pm	MT
Johnson & Johnson Completes Acquisition of Proteologix	12:37pm	MT
Johnson & Johnson Completes Acquisition of Proteologix	12:36pm	MT
Johnson & Johnson Completes Acquisition of Proteologix, Inc.	12:31pm	BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications	08:06am	AQ
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	20/06/2024	CI
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	06-20	MT
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	06-20	PR
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	06-20	CI
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	06-20	BU
J&J: launches open, secure digital ecosystem	06-20	CF
J&J: promising results in Crohn's disease	06-20	CF
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	06-20	MT
Johnson & Johnson Sees Positive Trial Results for Tremfya	06-20	DJ
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction	06-20	PR
Johnson & Johnson Announces Positive Topline Results from the Pivotal Phase 3 GRAVITI Investigational Study of TREMFYA® Subcutaneous (SC) Induction Therapy in Adult Patients with Moderate to Severe Active Crohn's Disease	06-20	CI
Johnson & Johnson - Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer	06-18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm